Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
Alejandro Campos-Murguía, Berenice M Román-Calleja, Israel Vicente Toledo-Coronado, José A González-Regueiro, Alberto Adrián Solís-Ortega, Deyanira Kúsulas-Delint, Mariana Cruz-Contreras, Nabila Cruz-Yedra, Francisco Javier Cubero, Yulia A. Nevzorova, Carlos Fernando Martínez-Cabrera, Paulina Moreno-Guillén, Oscar Arturo Lozano-Cruz, Mónica Chapa-Ibargüengoitia, Alfonso Gulı́as-Herrero, Carlos A. Aguilar‐Salinas, Astrid Ruiz‐Margáin, Ricardo Ulises Macías‐Rodríguez
Topics & Concepts
MedicineFatty liverCoronavirus disease 2019 (COVID-19)Risk factorLiver fibrosisInternal medicineFibrosisAdverse effectGastroenterologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease2019-20 coronavirus outbreakLiver diseasePathologyInfectious disease (medical specialty)OutbreakLiver Disease Diagnosis and TreatmentCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19